<DOC>
	<DOCNO>NCT02721576</DOCNO>
	<brief_summary>This perspective , multicenter , single arm , open label , Phase 2 study evaluate efficacy safety treatment CMNa combine concurrent chemoradiotherapy patient locally recurrent squamous cell esophageal carcinoma . Analyses primary objective ( ORR ) do define protocol .</brief_summary>
	<brief_title>A Trial CMNa Combined With Concurrent Chemoradiotherapy Locally Recurrent ESCC</brief_title>
	<detailed_description>The primary end point study objective response rate.The secondary end point OS , PFS safety drug . The primary hypothesis CMNa improve ORR thus improve OS , PFS . Assuming bilateral a=0.05 , statistical power 80 % . The total sample size 40 case .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Signed write informed consent prior study entry 2 . Patients recurrent ESCC radiotherapy , confirm image pathology cytology ; 3 . Capable chemoradiotherapy ; 4 . The existence measurable lesion ; 5 . ECOG PS 0 1 6 . Possible semiliquid diet ; 7 . Expected lifetime≥3 month 8. normal bone marrow reserve : ANC count ≥1500/mm3 ; platelet count ≥100,000/ mm3 , hemoglobin≥9g/dl 9. normal hepatic function : bilirubin level ≤1.5×ULN ; AST/ALT≤1.5×ULN 10. normal renal function : serum creatinine≤1.5mg/dl calculate creatinine clearance ≥60ml/min 11 . Normal cardiac function 12 . Subjects tumor tissue available relevant biomarker detection 13 . Clinical stage : No distant metastasis 1 . Female subject pregnancy lactation , subject fertility n't take effective contraception study 2 . Any mental illness nervous system lesion ca n't tell treatment response clearly ( cerebrovascular accident sequela ) 3 . Any serious uncontrolled disease infection , severe heart , liver , kidney disease diabetes , ca n't complete treatment plan 4 . Patients malignant lesion , except curable skin cancer ( nonmelanoma skin cancer ) , carcinoma situ cervix serve disease cure 5 year 5 . Patients distant metastasis . 6 . Patients obvious esophageal ulcer moderate pain chestback symptom esophageal perforation 7. receive anticancer treatment esophageal cancer group , include surgery , radiotherapy , chemotherapy ( induction chemotherapy group great equal two cycle ) 8 . Not esophageal squamous carcinoma confirm pathology cytology 9 . History active hepatitis 10 . Unable comprehend study requirement likely comply study requirement 11 . Significant disease , investigator 's opinion , would exclude patient study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>